Endotherapeutics is a leading Australian medical technology company specialising in the distribution of innovative medical devices and healthcare solutions.
Having previously self-represented in lease negotiations, Endotherapeutics chose to engage TRS to assess both renewal and relocation options. Their key objectives were to reduce operating costs and structure incentives in a way that could support capital works.
TRS provided detailed market knowledge on rents, incentives, and available space, enabling informed decision-making throughout the negotiation process.
The result was a renewal that achieved significant operating cost savings and maximised the value of incentives, providing both financial efficiency and long-term flexibility.